Contortrostatin

Drug Profile

Contortrostatin

Alternative Names: PB 2

Latest Information Update: 17 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Southern California
  • Developer Pivotal BioSciences; University of Southern California
  • Class Antiplatelets; Cytostatics; Disintegrins
  • Mechanism of Action Integrin inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours; Thrombosis

Most Recent Events

  • 14 Dec 2007 Preclinical development for Solid tumours is ongoing
  • 14 Dec 2007 Discontinued - Preclinical for Thrombosis in USA (IV)
  • 14 Jun 2004 Contortrostatin licensed to Pivotal BioSciences worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top